ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

praliciguat

Also written as “IW-1973”, “Praliciguat (Part A)” and “Praliciguat (Part B)”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Glomerulosclerosis, Focal Segmental · Heart Failure, led by 2 companies.

Drug pagePraliciguat: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 15, 20168 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticals50 open or runningphase 2since Sep 15, 2016Oct 29, 2015none ahead
Akebia Therapeuticsits history only31 open or runningphase 2since Jul 12, 2017Jul 12, 2017Jun 2027phase 2 · NCT07268638

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ironwood Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2015First study: phase 1 study in HealthyFirst studyNCT02616861 · 54 enrolled · United States
  2. Sep 15, 2016Phase 2 study in Diabetes Mellitus, Type 2NCT02906579 · 11 enrolled · United States
  3. Dec 9, 2016Named praliciguatINNProposed as its International Nonproprietary Name in WHO's List 116 · before, IW-1973
  4. Mar 8, 2017Phase 2 study in Diabetes Mellitus, Type 2NCT03091920 · 26 enrolled · United States
  5. Apr 9, 2018Phase 1 study in HealthyNCT03499106 · 24 enrolled · United States
  6. Jan 24, 2019Phase 1 study in Healthy VolunteersNCT03818295 · 8 enrolled · United States

TargetBeta

“Soluble guanylate cyclase activator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
Nitroglycerinrulemediquest-therapeuticsphase 414
ataciguatruleSanofiphase 33

Studies

All 5 Ironwood Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03818295Healthy Volunteers · United States1CompletedApr 24, 20198
NCT03499106Healthy · United States1CompletedJul 6, 201824
NCT03091920Diabetes Mellitus, Type 2 · United States2CompletedAug 3, 201726
NCT02906579Diabetes Mellitus, Type 2 · United States2CompletedMar 17, 201711
NCT02616861Healthy · United States1CompletedMay 201654

How it is read

Names in the registry

  • “IW-1973”, 7 entries
  • “Praliciguat (Part A)”, 1 entry
  • “Praliciguat (Part B)”, 1 entry
  • “[14C]-praliciguat”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.